Integrated BioPharma (OTCMKTS:INBP – Get Free Report) and Profound Medical (NASDAQ:PROF – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.
Profitability
This table compares Integrated BioPharma and Profound Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Integrated BioPharma | -3.43% | -8.32% | -6.57% |
| Profound Medical | -206.76% | -78.88% | -64.06% |
Valuation and Earnings
This table compares Integrated BioPharma and Profound Medical”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Integrated BioPharma | $54.35 million | 0.10 | $810,000.00 | ($0.07) | -2.58 |
| Profound Medical | $18.81 million | 12.81 | -$42.57 million | ($1.24) | -5.35 |
Integrated BioPharma has higher revenue and earnings than Profound Medical. Profound Medical is trading at a lower price-to-earnings ratio than Integrated BioPharma, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Integrated BioPharma and Profound Medical, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Integrated BioPharma | 0 | 0 | 0 | 0 | 0.00 |
| Profound Medical | 1 | 0 | 1 | 0 | 2.00 |
Profound Medical has a consensus price target of $12.00, suggesting a potential upside of 81.00%. Given Profound Medical’s stronger consensus rating and higher probable upside, analysts clearly believe Profound Medical is more favorable than Integrated BioPharma.
Insider and Institutional Ownership
25.3% of Integrated BioPharma shares are owned by institutional investors. Comparatively, 47.9% of Profound Medical shares are owned by institutional investors. 67.4% of Integrated BioPharma shares are owned by insiders. Comparatively, 1.5% of Profound Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Volatility and Risk
Integrated BioPharma has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500. Comparatively, Profound Medical has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.
Summary
Integrated BioPharma beats Profound Medical on 8 of the 14 factors compared between the two stocks.
About Integrated BioPharma
Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.
About Profound Medical
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.
Receive News & Ratings for Integrated BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integrated BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
